Lead Product(s) : ABL301
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.
Brand Name : ABL301
Molecule Type : Large molecule
Upfront Cash : $75.0 million
January 11, 2022
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
